Andrew Greene
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andrew Greene has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Althea Campuzano
Department of Biology, The University of Texas at San Antonio, San Antonio, TX, United States of America
1 shared publication - Chiung-Yu Hung
Department of Molecular Microbiology and Immunology, University of Texas at San Antonio, San Antonio, TX 78249, USA
1 shared publication - Edith Sánchez-Paredes
Unidad de Micología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
1 shared publication - Karin Ardon-Dryer
Department of Geosciences Atmospheric Science Group Texas Tech University Lubbock TX USA
1 shared publication - Kimberly Ann Kaufeld
Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
1 shared publication - Laura Rosio Castañón-Olivares
Universidad Nacional Autónoma de México
1 shared publication
Latest Publications
- Open Access
- 5 January 2023
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (1) , 83
Advocating for Coccidioidomycosis to Be a Reportable Disease Nationwide in the United States and Encouraging Disease Surveillance across North and South America
Coccidioidomycosis (Valley fever) has been a known health threat in the United States (US) since the 1930s, though not all states are currently required to report disease cases. Texas, one of the non-reporting states, is an example of where both historical and contemporary scientific evidence define the region as endemic, but we don’t know disease incidence in the state. Mandating coccidioidomycosis as a reportable disease across more US states would increase disease awareness, improve clinical outcomes, and help antifungal drug and vaccine development. It would also increase our understanding of where the disease is endemic and the relationships between environmental conditions and disease cases. This is true for other nations in North and South America that are also likely endemic for coccidioidomycosis, especially Mexico. This commentary advocates for US state and territory epidemiologists to define coccidioidomycosis as a reportable disease and encourages disease surveillance in other endemic regions across North and South America in order to protect human health and reduce disease burden.
- 5 January 2023
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (1) , 83
Open AccessAdvocating for Coccidioidomycosis to Be a Reportable Disease Nationwide in the United States and Encouraging Disease Surveillance across North and South America
Coccidioidomycosis (Valley fever) has been a known health threat in the United States (US) since the 1930s, though not all states are currently required to report disease cases. Texas, one of the non-reporting states, is an example of where both historical and contemporary scientific evidence define the region as endemic, but we don’t know disease incidence in the state. Mandating coccidioidomycosis as a reportable disease across more US states would increase disease awareness, improve clinical outcomes, and help antifungal drug and vaccine development. It would also increase our understanding of where the disease is endemic and the relationships between environmental conditions and disease cases. This is true for other nations in North and South America that are also likely endemic for coccidioidomycosis, especially Mexico. This commentary advocates for US state and territory epidemiologists to define coccidioidomycosis as a reportable disease and encourages disease surveillance in other endemic regions across North and South America in order to protect human health and reduce disease burden.